Sequencing Life-Prolonging Agents in Prostate Cancer | ESMO
Possible changes in the standard of care for prostate cancer
Women for Mankind: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
Expanding the Therapeutic Opportunities in Advanced Prostate Cancer | ESMO
Updated Therapeutic Approach of Castration-Resistant Prostate Cancer (CRPC) | ESMO
Advanced Prostate Cancer: How Do We Move Forward in Patient Management? | ESMO
Possible changes in the standard of care for prostate cancer
Exploring Questions in Metastatic Prostate Cancer | ESMO
ESMO Virtual Advanced Course on Clinical Questions in Prostate
ESMO Preceptorship on Prostate Cancer | Lugano 2019
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer - Biomarker analysis and updated results - touchONCOLOGY
ESMO 2020: PARP inhibitor olaparib for the targeted treatment of metastatic prostate cancer - ecancer
Women Against Prostate Cancer: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
ESMO Guidelines: Real World Cases - Webinar Series: March 2021
PDF) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Is Earlier Better? Translating Clinical Evidence into Individualised Treatment Decisions in Advanced Prostate Cancer | ESMO
Sequencing Strategies in Metastatic Prostate Cancer: Revealing the Cards | ESMO
Mapping Pathways for PARP Inhibition in Prostate Cancer: Practical Considerations for Clinical Practice | ESMO
Table 2 from Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Guidelines for genetic testing
ESMO 2022: Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy - Daily Reporter
Elucidate Metastatic Prostate Cancer Targets with Radioligand Therapy and Molecular Profiling: Advancing Precision Medicine in Prostate Cancer | ESMO
PEACE-1: OS in mCSPC - Capsule Summary Slidesets - ESMO 2021 - Oncology - Clinical Care Options
ESMO 2019: Invited Discussant: The CARD Trial – Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer – Philippine Endourological Society
